Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives
F Halter, A S Tarnawski, A Schmassmann, B M Peskar, F Halter, A S Tarnawski, A Schmassmann, B M Peskar
Abstract
Cyclooxygenase (COX), the key enzyme for synthesis of prostaglandins, exists in two isoforms (COX-1 and COX-2). COX-1 is constitutively expressed in the gastrointestinal tract in large quantities and has been suggested to maintain mucosal integrity through continuous generation of prostaglandins. COX-2 is induced predominantly during inflammation. On this premise selective COX-2 inhibitors not affecting COX-1 in the gastrointestinal tract mucosa have been developed as gastrointestinal sparing anti-inflammatory drugs. They appear to be well tolerated by experimental animals and humans following acute and chronic (three or more months) administration. However, there is increasing evidence that COX-2 has a greater physiological role than merely mediating pain and inflammation. Thus gastric and intestinal lesions do not develop when COX-1 is inhibited but only when the activity of both COX-1 and COX-2 is suppressed. Selective COX-2 inhibitors delay the healing of experimental gastric ulcers to the same extent as non-COX-2 specific non-steroidal anti-inflammatory drugs (NSAIDs). Moreover, when given chronically to experimental animals, they can activate experimental colitis and cause intestinal perforation. The direct involvement of COX-2 in ulcer healing has been supported by observations that expression of COX-2 mRNA and protein is upregulated at the ulcer margin in a temporal and spatial relation to enhanced epithelial cell proliferation and increased expression of growth factors. Moreover, there is increasing evidence that upregulation of COX-2 mRNA and protein occurs during exposure of the gastric mucosa to noxious agents or to ischaemia-reperfusion. These observations support the concept that COX-2 represents (in addition to COX-1) a further line of defence for the gastrointestinal mucosa necessary for maintenance of mucosal integrity and ulcer healing.
Figures
References
- Gastroenterology. 1992 Jan;102(1):168-74
- Cell. 1995 Nov 3;83(3):473-82
- Arch Biochem Biophys. 1998 Apr 1;352(1):153-7
- Gastroenterology. 1995 Sep;109(3):681-91
- BMJ. 1988 Oct 22;297(6655):1017-21
- Inflamm Res. 1998 Oct;47 Suppl 2:S88-92
- Gastroenterology. 1995 Aug;109(2):524-30
- Gastroenterology. 1997 Jul;113(1):195-204
- Stroke. 1998 Jul;29(7):1423-9; discussion 1429-30
- Br J Pharmacol. 1990 Mar;99(3):607-11
- J Biol Chem. 1991 Jul 15;266(20):12866-72
- Ann Rheum Dis. 1979 Feb;38(1):14-7
- Am J Physiol. 1998 May;274(5 Pt 1):G955-64
- Gastroenterology. 2000 Mar;118(3):487-96
- Arch Intern Med. 1996 Jul 22;156(14):1530-6
- Hypertension. 1997 Sep;30(3 Pt 2):687-92
- J Pharmacol Exp Ther. 1999 Aug;290(2):551-60
- Cell. 1995 Nov 3;83(3):483-92
- Gastroenterology. 1992 Jul;103(1):146-52
- Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272-7
- Prostaglandins Other Lipid Mediat. 1998 Aug;56(5-6):341-61
- Ann Intern Med. 1991 Aug 1;115(3):195-200
- J Clin Gastroenterol. 1998;27 Suppl 1:S21-7
- Gastroenterology. 1999 Jun;116(6):1305-9
- Gastroenterology. 1979 Sep;77(3):433-43
- JAMA. 2000 Sep 13;284(10):1247-55
- Eur J Immunol. 1991 Feb;21(2):243-50
- Am J Physiol. 1990 Sep;259(3 Pt 1):G462-7
- N Engl J Med. 1998 Mar 12;338(11):719-26
- Aliment Pharmacol Ther. 2000 May;14(5):639-50
- Neuron. 1993 Aug;11(2):371-86
- Am J Health Syst Pharm. 1999 Mar 1;56(5):403
- Schweiz Med Wochenschr. 1996 Apr 13;126(15):616-25
- J Pharmacol Exp Ther. 1995 Sep;274(3):1531-7
- Aliment Pharmacol Ther. 1993 Feb;7(1):41-5
- J Surg Res. 1998 Feb 1;74(2):119-24
- Nat Med. 1999 Dec;5(12):1418-23
- Br J Pharmacol. 1991 Mar;102(3):759-63
- Mol Pharmacol. 1998 Sep;54(3):536-40
- Gastroenterology. 1989 Feb;96(2 Pt 1):393-402
- Br J Pharmacol. 2001 Apr;132(7):1565-73
- J Clin Invest. 1996 Nov 1;98(9):2076-85
- Am J Gastroenterol. 1999 May;94(5):1218-23
- Scand J Gastroenterol. 1988 Jun;23(5):585-90
- Br J Pharmacol. 1998 Mar;123(5):795-804
- Br J Pharmacol. 1999 Dec;128(8):1659-66
- Am J Physiol. 1995 Feb;268(2 Pt 1):G276-85
- Am J Physiol. 1998 Nov;275(5 Pt 1):G1137-45
- Gastroenterology. 1999 Oct;117(4):776-83
- Br J Pharmacol. 1998 Mar;123(5):927-35
- Neurology. 1997 Mar;48(3):626-32
- Gastroenterology. 1988 Aug;95(2):327-33
- Lancet. 1999 Jan 23;353(9149):307-14
- Lancet. 1998 Jan 3;351(9095):61; author reply 61-2
- Clin Exp Pharmacol Physiol. 1996 May;23(5):432-4
- Dig Dis Sci. 1998 Sep;43(9):2003-11
- Cancer Res. 1996 Jun 1;56(11):2556-60
- Clin Ther. 1999 Jun;21(6):992-1003
- Am J Physiol. 1992 Jun;262(6 Pt 1):G1138-42
- Gastroenterology. 1998 Jul;115(1):101-9
- N Engl J Med. 1993 May 6;328(18):1313-6
- J Pharmacol Exp Ther. 1957 Aug;120(4):540-5
- Gastroenterology. 1988 Sep;95(3):636-41
- Lancet. 1994 Apr 30;343(8905):1075-8
- Aliment Pharmacol Ther. 1995 Jun;9(3):227-35
- Am J Gastroenterol. 1991 Aug;86(8):961-4
- Gut. 2000 Dec;47(6):762-70
- J Exp Med. 1998 Feb 16;187(4):517-23
- Annu Rev Physiol. 1995;57:565-83
- Lancet. 1999 Dec 18-25;354(9196):2106-11
- Histochem J. 1995 Apr;27(4):323-8
- J Clin Invest. 1994 Dec;94(6):2504-10
- Cancer Res. 1996 Feb 15;56(4):710-4
- Gastroenterology. 1999 Feb;116(2):254-8
- Nat Med. 1999 Aug;5(8):900-6
- BMJ. 1990 Feb 3;300(6720):278-84
- FEBS Lett. 1993 Sep 13;330(2):156-60
- Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7
- FASEB J. 1999 Feb;13(2):245-51
- Nat Med. 1995 Feb;1(2):154-8
- Gut. 1995 Mar;36(3):334-6
- Gastroenterology. 1994 Oct;107(4):1183-8
- Gastroenterology. 1994 Jul;107(1):173-9
- Gastroenterology. 1997 Jul;113(1):15-24
- Gastroenterology. 2000 Mar;118(3):640-1
- Br J Pharmacol. 1992 Jan;105(1):171-5
- FASEB J. 1999 Dec;13(15):2186-94
- Prostaglandins Leukot Essent Fatty Acids. 1998 Nov;59(5):313-6
- Gastroenterology. 1999 Jun;116(6):1319-29
- Lancet. 1986 Nov 8;2(8515):1084-7
- Eur J Clin Invest. 1990 Aug;20(4):432-40
- J Clin Gastroenterol. 1997;25 Suppl 1:S105-10
- Inflammopharmacology. 1997;5(4):407-14
- Aliment Pharmacol Ther. 1999 Nov;13(11):1511-8
- Cancer Res. 2000 Apr 15;60(8):2101-3
- Am J Physiol. 1991 Sep;261(3 Pt 1):G470-5
- Cell. 1996 Nov 29;87(5):803-9
- Gastroenterology. 1997 Feb;112(2):387-97
- Prostaglandins Other Lipid Mediat. 1999 Aug;58(1):9-17
- Aliment Pharmacol Ther. 1997 Dec;11(6):1101-8
- Am J Physiol. 1992 Dec;263(6 Pt 1):G920-6
- Eur J Pharmacol. 1992 Nov 13;223(1):103-4
- N Engl J Med. 1999 Jun 24;340(25):2005-6
- Scand J Gastroenterol Suppl. 1989;163:24-31
- Gastroenterology. 1991 May;100(5 Pt 1):1259-65
- Lancet. 1990 Oct 6;336(8719):840-3
- Gastroenterology. 1998 Feb;114(2):245-55
- Gut. 1999 Apr;44(4):448-9
- Nat New Biol. 1971 Jun 23;231(25):232-5
- Lancet. 1998 Sep 26;352(9133):1016-21
- Am J Physiol. 1992 May;262(5 Pt 1):G903-8
- Nature. 1994 Jan 20;367(6460):215-6
- Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4651-5
- Am J Physiol. 1987 Mar;252(3 Pt 1):G421-30
- JAMA. 1999 Nov 24;282(20):1921-8
- J Clin Invest. 1988 Apr;81(4):1081-9
- Arthritis Rheum. 2000 Feb;43(2):370-7
- Am J Physiol. 1993 Nov;265(5 Pt 1):G993-8
- J Pharmacol Exp Ther. 1998 Oct;287(1):301-6
- Gastroenterology. 2000 Sep;119(3):706-14
- Nature. 1990 Jan 4;343(6253):82-5
- BMJ. 1996 Jun 22;312(7046):1563-6
- Ann Rheum Dis. 1996 Apr;55(4):211-3
- Dig Dis Sci. 1991 May;36(5):594-600
- Carcinogenesis. 1995 May;16(5):1023-8
- Gut. 1993 Jun;34(6):742-7
- Br J Rheumatol. 1993 Nov;32(11):990-5
- Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2692-6
- Ann Surg. 1987 Apr;205(4):399-403
- Gastroenterology. 1993 Jun;104(6):1832-47
- J Biol Chem. 1998 Oct 30;273(44):28560-3
- J Rheumatol Suppl. 1991 Mar;28:11-4
- Lancet. 1997 Oct 4;350(9083):975-9
- Aliment Pharmacol Ther. 1997 Feb;11(1):69-79
- Am Heart J. 1999 Apr;137(4 Pt 2):S9-S13
- Cleve Clin J Med. 1999 May;66(5):285-92
Source: PubMed